Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label Paclitaxel. Show all posts
Showing posts with label Paclitaxel. Show all posts
Saturday, July 07, 2012

paywalled- Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis

›
Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis Abstract Background ...
Thursday, May 17, 2012

paywalled- Gynecologic Oncology - Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer ($8,699,872 monthly.

›
ScienceDirect.com - Gynecologic Oncology - Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer Object...
Wednesday, April 25, 2012

Current Drug Shortages: Paclitaxel Injection (updated)

›
Current Drug Shortages: Paclitaxel Injection (updated) : APP is currently back-ordered on 100 mg/16.7 mL vial (NDC 63323-0763-16) and 300 ...
Tuesday, April 24, 2012

Current Drug Shortages: Paclitaxel Injection (updated)

›
Current Drug Shortages: Paclitaxel Injection (updated) : Teva has all presentations available with ample inventory.

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids - Full Text View - ClinicalTrials.gov

›
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids - Full Text View - ClinicalTrials.gov This study is currently recruitin...
Saturday, April 21, 2012

abstract: Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and non small cell lung cancer and its role in survival and toxicity.

›
  Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and no...
Tuesday, March 27, 2012

abstract: Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer (astounding figures)

›
Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer - NCBI Abstract OBJECTIVE: To determine the p...
Wednesday, March 21, 2012

abstract: Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy - Reeves - 2012 - Cancer - Wiley Online Library

›
Blogger's Opinion : since this journal is a publication of the ACS then open access should be mandated Further data supporting that pa...
Saturday, March 17, 2012

abstract: Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

›
Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Abstract PURPOSE:...
Friday, March 16, 2012

Current Drug Shortages: Paclitaxel (Taxol) Injection (updated)

›
Current Drug Shortages: Paclitaxel Injection (updated) : Hospira product 30 mg/5 mL vial (NDC 0409-0342-09): ample levels of inventory to ...
Sunday, March 11, 2012

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

›
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal...
Friday, March 02, 2012

FDA U.S. Drug Shortages - Paclitaxel (Taxol)

›
Paclitaxel Injection (updated 3/2/2012) Company/Products Reason Related Information ...
Wednesday, February 01, 2012

abstract: Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial

›
Background: In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carbopl...
Tuesday, January 24, 2012

abstract: Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial (GINECO)

›
Conclusions: Combination chemotherapy in platinum-resistant ROC ( recurrent ovarian cancer ) was more toxic than weekly paclitaxel and did...
Wednesday, January 18, 2012

A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome.

›
Abstract Objective : We investigated the efficacy of risk-adapted adjuvant paclitaxel/carboplatin chemotherapy in early-stage ovarian c...
Tuesday, January 03, 2012

Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal C... : International Journal of Gynecological Cancer

›
Objective: This study aimed to evaluate intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin (TCipTip therapy) feasibility...

Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer

›
  Objectives:  The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a s...
Thursday, December 29, 2011

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

›
Highlights ► The maximum tolerated dose and feasibility of IV and IP chemotherapy was assessed. ► The dose limiting toxicity rate f...
Wednesday, July 13, 2011

Cochrane review: Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma.

›
OBJECTIVES: To assess the effectiveness and toxicity of short versus long infusions of paclitaxel for any advanced adenocarcinoma. ...
Monday, July 11, 2011

Abstract/full free access: Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/ refractory epithelial ovarian cancer

›